| Name | Title | Contact Details |
|---|
Afero is the leading secure IoT Platform as a Service. Afero technology incorporates simplicity, ease of use, security, and data privacy into the entire solution, from manufacturing to product to cloud to end user. The Afero platform uniquely secures your entire supply chain while providing your customers with end-to-end encryption, fast onboarding, and direct to device failover. With Afero, products get to market 3x faster, have 10x higher attach rates, and have 99% fewer customer escalations. This user-friendly, fast, and secure IoT platform unlocks smart and connected capabilities for any product, vertical, sector, or industry, whether large or tiny, fixed or mobile. Afero`s world-class team is composed of mobile, hardware, security, and cloud veterans from Google, Apple, Nest, Symantec, Danger, Microsoft, Amazon, Twitter, Netflix and other leading platform companies.
We know what`s on the line for our customers. We know that success depends on meeting challenges head-on and taking risks, but that shouldn`t be in the partnerships our customers engage in to get things done. At Collaborative, we believe the product of expertise, value and trust is integrity in all our relationships. Our approach to solving business problems for clients is biased towards action and pragmatism. To do this effectively, we need extraordinary people – and we have them to get IT right the first time, without the unnecessary big brand overhead. As our name implies, our strength is in genuine collaboration—the sharing of ideas and vision to help ensure successful outcomes. We have the expertise to be trusted with difficult and complicated initiatives, and the resources to provide full lifecycle support from development to execution. We understand what getting mission-critical initiatives done means, and we are honest about the right path to get there. Most of all, we have the integrity to stand by our promises no matter what.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Janams rugged mobile computers provide your mobile workers with the technology needed to get the job done.
Experience the worlds most advanced digital night vision. The SIONYX Aurora is an ultra low-light digital camera systems that literally turn night into day with full color night vision capabilities. The Digital Future is now. See in the dark with full...